Clinical trials: Early Parkinson's Disease
Parkinson's Disease
A Study of the Safety and Tolerability of a Single Dose Administration of CVT-301 (Levodopa Inhalation Powder)
This study is a double-blind, randomized, placebo-controlled, 2-way crossover study to evaluate the safety of CVT-301 levodopa (l-dopa) when co- administered with the first daily dose of oral levodopa/carbidopa for early morning…
- Trial name
- NCT02807675
- Testing
- CVT-301, LIP
- Where
- 11 sites in United States
- Volunteers
- 36 people
- Sponsor
- Acorda Therapeutics
Parkinson's Disease
Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist (12 Month Extension)
To determine the long-term safety and efficacy of a dose range of safinamide of 50-200 mg/day, p.o., compared to placebo, as add-on therapy in patients with early idiopathic Parkinson's disease who are currently receiving a…
- Trial name
- NCT00642889
- Testing
- Safinamide
- Volunteers
- 227 people
- Sponsor
- Newron Pharmaceuticals SPA
Parkinson's Disease
Study to Assess Real Life Effectiveness of Foslevodopa/Foscarbidopa in Adult German Participants at Initial Stages of Advanced Parkinson's Disease (EARLY-FOS)
Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot from person to person.
- Trial name
- NCT06916507
- Where
- 19 sites in Germany
- Volunteers
- 125 people
- Sponsor
- AbbVie
Parkinson's Disease, Healthy
Single-Ascending Dose Study of BIIB054 in Healthy Participants and Early Parkinson's Disease
The primary objective of the study is to evaluate the safety and tolerability of a range of single BIIB054 doses, administered as a single intravenous (IV) infusion, in healthy participants and participants with early Parkinson's…
- Trial name
- NCT02459886
- Testing
- BIIB054
- Where
- 9 sites in United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Biogen
Parkinson Disease
Efficacy, Safety, Tolerability, and Biomarker Effects of GT-02287 in Early Parkinson's Disease
The purpose of this study is to assess the efficacy, the safety, and the effect on biomarkers of 2 dose levels of oral GT-02287 over placebo after 48 weeks of treatment in treated and untreated participants with early PD.
- Trial name
- NCT07280299
- Testing
- Low Dose GT-02287, High Dose GT-02287
- Volunteers
- 111 people
- Sponsor
- Gain Therapeutics, Inc.
Parkinson's Disease
Investigation of Cogane (PYM50028) in Early-stage Parkinson's Disease (CONFIDENT-PD)
A study to test the therapeutic benefit of the compound PYM50028, versus placebo, in treating early-stage Parkinson's disease. Therapeutic benefit will be assessed using the Unified Parkinson's Disease Rating Scale (UPDRS).
- Trial name
- CONFIDENT-PD (NCT01060878)
- Testing
- PYM50028
- Where
- 111 sites in United States, Canada and 8 more
- Volunteers
- 425 people
- Sponsor
- Phytopharm
Parkinson Disease
Ophthalmologic Safety Study of Pramipexole Immediate Release (IR) Versus Ropinirole in Early Parkinson's Disease (PD) Patients
To determine if there is any difference in the presence of retinal deterioration in PD patients treated with pramipexole IR versus ropinirole as monitored by comprehensive ophthalmologic assessments from baseline to the end of…
- Trial name
- NCT00144300
- Testing
- Mirapex, Requip
- Where
- 21 sites in United States
- Volunteers
- 246 people
- Sponsor
- Boehringer Ingelheim
Parkinson's Disease
Randomized Evaluation of the 24-Hour Coverage: Efficacy of Rotigotine
The objective of this trial is to assess the effects of transdermal rotigotine on the control of early morning motor function and sleep disorders compared to placebo in subjects with idiopathic Parkinsons´s disease.
- Trial name
- RECOVER (NCT00474058)
- Testing
- Rotigotine
- Where
- 47 sites in United States, Australia and 10 more
- Volunteers
- 287 people
- Sponsor
- UCB Pharma
Parkinson's Disease
A Phase 3 Study of TVP-1012 (1 mg) in Early Parkinson's Disease Patients
The purpose of this study is to evaluate the efficacy and safety of TVP-1012 (1 mg/day) administered to Japanese patients with early Parkinson's disease.
- Trial name
- NCT02337725
- Testing
- TVP-1012
- Where
- 55 sites in Japan
- Volunteers
- 244 people
- Sponsor
- Takeda
Parkinson Disease
REal-life ON PARKinson's - ITaly (REONPARK-IT)
The present study aims to evaluate the effectiveness and safety of opicapone in a real-world setting at centers for Parkinson's disease located in Italy.
- Trial name
- NCT07403799
- Testing
- Opicapone 50 mg
- Where
- 20 sites in Italy
- Volunteers
- 200 people
- Sponsor
- Bial - Portela C S.A.
Early Parkinson Disease
PROSEEK: A Phase 2 Study In Early Parkinson's Disease Patients Evaluating The Safety And Efficacy Of Abl Tyrosine Kinase Inhibition Using K0706
This study consists of 2 parts. Part 1 of the study is conducted to evaluate the efficacy, safety, and tolerability of two doses of K0706 compared to placebo in subjects with early Parkinson's Disease who are not receiving…
- Trial name
- NCT03655236
- Testing
- K0706
- Where
- 78 sites in United States, Hungary and 4 more
- Volunteers
- 513 people
- Sponsor
- Sun Pharma Advanced Research Company Limited
Parkinson Disease, Neurodegenerative Diseases
Study Assessing Tolerability and Safety of AFFITOPE® PD03A in Patients With Early Parkinson's Disease
Study AFF011 is a randomized controlled parallel Group phase I study to investigate the safety and tolerability of two doses of the vaccine AFFITOPE® PD03A given to patients with early Parkinson's disease.
- Trial name
- AFF011 (NCT02267434)
- Testing
- Low dose AFFITOPE® PD03A + Adjuvant, High dose AFFITOPE® PD03A + Adjuvant, Adjuvant without active component
- Where
- 2 sites in Austria
- Volunteers
- 36 people
- Sponsor
- Affiris AG
Parkinson Disease
Study on the Safety, Tolerance and Pharmacokinetics of Phenlarmide Tablets
1. To evaluate the safety and tolerability of Phenlarmide tablets in patients with Parkinson's disease in the early and middle stages. 2.
- Trial name
- NCT04693039
- Testing
- Phenlarmide
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shijiazhuang Yiling Pharmaceutical Co. Ltd
Early Stage Parkinson's Disease
The Effects of Aplindore on the Treatment of Signs and Symptoms of Parkinson's Disease
The purpose of this study is to demonstrate the safety, tolerability, efficacy and pharmacokinetics of aplindore in patients with early stage Parkinson's Disease (PD) who are not currently taking any dopamine agonists or who are…
- Trial name
- NCT00623324
- Testing
- Aplindore
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Ligand Pharmaceuticals
Parkinson's Disease
Pharmacokinetics and Safety Study of LY03003 in Patients With Early-stage Parkinson's Disease
The purpose of this study is to characterize the pharmacokinetics (PK) of LY03003 following multiple escalating intramuscular injections, as compared to Neupro patch and to evaluate the safety and tolerability and preliminary…
- Trial name
- 03003MAD (NCT02055274)
- Testing
- LY03003, Neupro
- Where
- 5 sites in United States
- Volunteers
- 39 people
- Sponsor
- Luye Pharma Group Ltd.
Parkinson's Disease
Dose-Finding Safety Study of BIIB014 in Early-Stage Parkinson's Disease
The main purpose of this study is to determine the safety of BIIB014 and how well BIIB014 is tolerated when given at different doses to patients with early-stage Parkinson's Disease.
- Trial name
- MOBILE (NCT00442780)
- Testing
- BIIB014
- Where
- 10 sites in Israel, Poland and 1 more
- Volunteers
- 36 people
- Sponsor
- Biogen
Parkinson Disease
Randomized, Double-Blind Clinical Trial for Parkinson's Disease (Early and Moderate)
This is a randomized, double-blind, single center, phase 2 study to assess efficacy and safety of multiple HB-adMSCs vs Placebo for the treatment of Parkinson's disease.
- Trial name
- PD (NCT04928287)
- Testing
- HB-adMSCs
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Hope Biosciences Research Foundation
Parkinson Disease
A Clinical Study of KDT-3594 in Japanese Patients With Early Parkinson's Disease
Objective of this study is to investigate the safety, pharmacokinetics and efficacy of KDT-3594 in patients with early Parkinson's disease without a concomitant medication of L-dopa.
- Trial name
- NCT04867551
- Testing
- KDT-3594
- Where
- Japan
- Volunteers
- 7 people
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
Parkinson Disease
A Placebo- and Active-Controlled Study of Preladenant in Early Parkinson's Disease (PD) (P05664)
This is a one year, 2-part study to determine the efficacy and safety of preladenant, an adenosine type 2a (A2a) receptor antagonist.
- Trial name
- PARADYSE (NCT01155479)
- Testing
- Preladenant 2 mg tablet, Preladenant 5 mg tablet, Preladenant 10 mg tablet
- Volunteers
- 1,022 people
- Sponsor
- Merck Sharp & Dohme LLC
Parkinson's Disease
A Phase 3, Long-term, Extension Study of TVP-1012 (1 mg) in Early Parkinson's Disease Participants
The purpose of this study is to evaluate the long-term safety of TVP-1012 (1 mg/day) in Japanese participants with early Parkinson's disease.
- Trial name
- NCT02337751
- Testing
- TVP-1012 1mg
- Where
- 56 sites in Japan
- Volunteers
- 198 people
- Sponsor
- Takeda